HUE044659T2 - Feljavított oldhatóságú szilárd diszperzió, amely tetrazol származékot tartalmaz hatóanyagként - Google Patents

Feljavított oldhatóságú szilárd diszperzió, amely tetrazol származékot tartalmaz hatóanyagként

Info

Publication number
HUE044659T2
HUE044659T2 HUE13863463A HUE044659T2 HU E044659 T2 HUE044659 T2 HU E044659T2 HU E13863463 A HUE13863463 A HU E13863463A HU E044659 T2 HUE044659 T2 HU E044659T2
Authority
HU
Hungary
Prior art keywords
active ingredient
solid dispersion
improved solubility
tetrazole derivative
tetrazole
Prior art date
Application number
Other languages
English (en)
Inventor
Yong Il Kim
Jun Young Choi
Young Keun Choi
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of HUE044659T2 publication Critical patent/HUE044659T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE13863463 2012-12-13 2013-12-12 Feljavított oldhatóságú szilárd diszperzió, amely tetrazol származékot tartalmaz hatóanyagként HUE044659T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120145603A KR101986683B1 (ko) 2012-12-13 2012-12-13 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체

Publications (1)

Publication Number Publication Date
HUE044659T2 true HUE044659T2 (hu) 2019-11-28

Family

ID=50934681

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13863463 HUE044659T2 (hu) 2012-12-13 2013-12-12 Feljavított oldhatóságú szilárd diszperzió, amely tetrazol származékot tartalmaz hatóanyagként

Country Status (38)

Country Link
US (1) US9283218B2 (hu)
EP (1) EP2931720B1 (hu)
JP (1) JP6355645B2 (hu)
KR (1) KR101986683B1 (hu)
CN (1) CN104870443B (hu)
AR (2) AR093706A1 (hu)
AU (1) AU2013360544B2 (hu)
BR (1) BR112015013905A2 (hu)
CA (1) CA2892376C (hu)
CL (1) CL2015001551A1 (hu)
CR (1) CR20150361A (hu)
DK (1) DK2931720T3 (hu)
DO (1) DOP2015000128A (hu)
EC (1) ECSP15029808A (hu)
ES (1) ES2731806T3 (hu)
GT (1) GT201500123A (hu)
HU (1) HUE044659T2 (hu)
IL (1) IL239327A (hu)
JO (1) JO3534B1 (hu)
LT (1) LT2931720T (hu)
MX (1) MX363644B (hu)
MY (1) MY174746A (hu)
NI (1) NI201500073A (hu)
NZ (1) NZ709071A (hu)
PE (1) PE20151066A1 (hu)
PH (1) PH12015501312A1 (hu)
PL (1) PL2931720T3 (hu)
PT (1) PT2931720T (hu)
PY (1) PY1358434A (hu)
RU (1) RU2662819C2 (hu)
SA (1) SA515360535B1 (hu)
SG (1) SG11201504067SA (hu)
SI (1) SI2931720T1 (hu)
TR (1) TR201908746T4 (hu)
TW (1) TWI652073B (hu)
UY (1) UY35186A (hu)
WO (1) WO2014092489A1 (hu)
ZA (1) ZA201503795B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102044223B1 (ko) * 2016-09-12 2019-11-13 성균관대학교산학협력단 텔미사르탄을 포함하는 고체 분산체 및 이의 제조방법
AU2019231699B2 (en) * 2018-03-07 2023-03-09 Andrew Xian Chen Aqueous formulations for insoluble drugs
CZ2018188A3 (cs) * 2018-04-18 2019-10-30 Zentiva, K.S. Částice s obsahem amorfního empagliflozinu, způsob jejich přípravy a farmaceutický přípravek
CN113631166A (zh) * 2018-12-14 2021-11-09 慧源香港创新有限公司 用于治疗癌症的口服给药的伊立替康和P-gp抑制剂的治疗组合
US10849893B2 (en) 2018-12-14 2020-12-01 Athenex HK Innovative Limited Therapeutic combinations of orally administered docetaxel and a P-gp inhibitor for the treatment of cancer
WO2020168144A1 (en) 2019-02-14 2020-08-20 Teva Pharmaceuticals International Gmbh Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(lh)- isoquinolinyl)ethyl] phenyl }-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl] -4- oxo-4h-chromene-2-carboxamide and of its mesylate salt
WO2022011221A1 (en) 2020-07-10 2022-01-13 Teva Czech Industries S.R.O Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide mesylate salt
WO2022076663A1 (en) 2020-10-07 2022-04-14 Athenex, Inc. Acetamido-phenyltetrazole derivatives and methods of using the same
CN116367836A (zh) * 2020-10-30 2023-06-30 艾斯尼克斯研发有限责任公司 Hm30181甲磺酸盐的多晶态

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
JP2000309588A (ja) * 1999-04-28 2000-11-07 Taisho Pharmaceut Co Ltd 固体分散体
CA2534371A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
KR100572411B1 (ko) * 2003-10-23 2006-04-18 한미약품 주식회사 열역학적으로 안정한 무정형 토라세미드 고체분산체와이를 포함하는 약학 조성물 및 이의 제조 방법
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
PT1926476E (pt) * 2005-08-29 2013-07-10 Sanofi Aventis Us Llc Dispersões sólidas amorfas de 7-cloro-n,n,5-trimetil-4-oxo-3- fenil-3,5-di-hidro-4h-piridazino[4,5-b]indole-1-acetamida
KR101466245B1 (ko) * 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
KR20110132116A (ko) * 2010-06-01 2011-12-07 (주)국전약품 라록시펜 염산염을 포함하는 고체분산체, 이의 제조방법, 및 이를 포함하는 경구용 제제
RU2566716C2 (ru) * 2010-06-09 2015-10-27 Эббви Бахамаз Лтд. Твердые дисперсии, содержащие ингибиторы киназ

Also Published As

Publication number Publication date
IL239327A0 (en) 2015-07-30
CA2892376C (en) 2020-10-27
EP2931720A1 (en) 2015-10-21
RU2662819C2 (ru) 2018-07-31
PT2931720T (pt) 2019-06-25
TR201908746T4 (tr) 2019-07-22
SA515360535B1 (ar) 2017-07-17
AU2013360544B2 (en) 2017-05-11
EP2931720A4 (en) 2016-06-29
MY174746A (en) 2020-05-13
GT201500123A (es) 2018-10-08
US20150272943A1 (en) 2015-10-01
IL239327A (en) 2017-11-30
AR093706A1 (es) 2015-06-17
MX2015006416A (es) 2015-08-14
PH12015501312B1 (en) 2015-08-24
SI2931720T1 (sl) 2019-08-30
EP2931720B1 (en) 2019-04-24
DK2931720T3 (da) 2019-07-08
JO3534B1 (ar) 2020-07-05
KR101986683B1 (ko) 2019-06-10
CN104870443A (zh) 2015-08-26
TWI652073B (zh) 2019-03-01
JP6355645B2 (ja) 2018-07-11
AR123783A2 (es) 2023-01-11
PL2931720T3 (pl) 2019-09-30
PH12015501312A1 (en) 2015-08-24
UY35186A (es) 2014-07-31
CN104870443B (zh) 2018-09-14
PY1358434A (es) 2017-01-02
NI201500073A (es) 2016-01-06
PE20151066A1 (es) 2015-08-11
US9283218B2 (en) 2016-03-15
LT2931720T (lt) 2019-07-10
KR20140076979A (ko) 2014-06-23
CL2015001551A1 (es) 2015-09-25
CA2892376A1 (en) 2014-06-19
ECSP15029808A (es) 2016-01-29
CR20150361A (es) 2015-08-21
WO2014092489A1 (en) 2014-06-19
AU2013360544A1 (en) 2015-07-09
MX363644B (es) 2019-03-29
NZ709071A (en) 2019-08-30
JP2016507489A (ja) 2016-03-10
ZA201503795B (en) 2016-08-31
TW201429507A (zh) 2014-08-01
DOP2015000128A (es) 2015-09-30
ES2731806T3 (es) 2019-11-19
HK1212330A1 (en) 2016-06-10
RU2015128002A (ru) 2017-01-16
SG11201504067SA (en) 2015-06-29
BR112015013905A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
TWI561171B (en) Active compound combinations
ZA201503795B (en) Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient
PL2836072T3 (pl) Kompozycja chwastobójcza zawierająca związek uracylowy jako składnik czynny
HUE039664T2 (hu) N-Arilamidinnel szubsztituált trifluoretil-szulfid-származékok mint atka- és rovarirtószerek
IL237467B (en) Nicotine preparation
IL238328A0 (en) Stable preparations that include peracetic acid
ZA201306000B (en) Stable formulation
ZA201407677B (en) Nicotine formulation
ZA201308371B (en) Sustained release pheromone formulation
ZA201504520B (en) Active ingredient microparticles
ZA201306643B (en) Formulation comprising phenylaminopyrimidine derivatives as active agent
GB201320585D0 (en) Insecticidal compounds based on arylthiosulfonamide derivatives
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
GB201210530D0 (en) Extended release formulations
AU2012903717A0 (en) Stabilizing drawbar mounting device
IL234771B (en) Nicotine formulation
PT2934506T (pt) Derivados de glutamato para utilização tópica como princípio ativo imunomodulador
AU2012904552A0 (en) An Improved Towball
AU2012901816A0 (en) Lactate-rich animal feeds